Introduction to RPH3AL-AS1 (G100506388)

Target Name: RPH3AL-AS1

NCBI ID: G100506388

RPH3AL-AS1

Other Name(s): RPH3AL antisense RNA 1 | LOC100506388 variant 1 | Uncharacterized protein LOC100506388 | Uncharacterized LOC100506388, transcript variant 1

Introduction to RPH3AL-AS1

RPH3AL-AS1 is a long non-coding RNA (lncRNA) that has gained attention in the field of biomedical research due to its potential role as a drug target or biomarker. In this article, we will explore the characteristics of RPH3AL-AS1 and discuss its significance in various diseases.

Understanding RPH3AL-AS1:

RPH3AL-AS1, also known as Rabphilin 3A-like 1 antisense RNA 1, is a non-coding RNA that does not encode proteins. It is transcribed from the antisense strand of the RPH3AL gene, located on chromosome 22q13.2. Originally considered a "junk DNA," lncRNAs like RPH3AL-AS1 have been found to play critical roles in gene regulation and various cellular processes.

Characteristics and Expression:

RPH3AL-AS1 is a relatively long lncRNA, consisting of over 2000 nucleotides. It displays tissue-specific expression, with higher expression levels observed in certain tissues compared to others. For instance, RPH3AL-AS1 has been found to be abundantly expressed in the central nervous system and various cancer tissues.

Role in Diseases:

1. Cancer: Emerging evidence suggests that RPH3AL-AS1 has a potential role in cancer development and progression. Studies have shown that RPH3AL-AS1 is upregulated in several types of cancer, including gastric cancer, colorectal cancer, and hepatocellular carcinoma. The overexpression of RPH3AL-AS1 has been associated with tumor growth, invasion, and metastasis. Consequently, targeting RPH3AL-AS1 has been proposed as a therapeutic strategy for cancer treatment.

2. Neurological Disorders: Due to its preferential expression in the central nervous system, RPH3AL-AS1 has also been implicated in neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease. This lncRNA has been found to contribute to the pathogenesis of these diseases by influencing neuronal survival, synaptic plasticity, and protein aggregation. Additionally, altered expression levels of RPH3AL-AS1 have been observed in post-mortem brain tissues of affected individuals.

3. Cardiovascular Diseases: Recent studies have suggested that RPH3AL-AS1 may play a role in cardiovascular diseases. Specifically, it has been shown to be upregulated in patients with heart failure and atherosclerosis. The dysregulation of RPH3AL-AS1 in these conditions suggests its potential as a biomarker for disease progression and prognosis. Moreover, targeted interventions against RPH3AL-AS1 may offer new therapeutic avenues for the management of cardiovascular disorders.

Potential as a Drug Target:

Given its involvement in various disease processes, RPH3AL-AS1 has emerged as a potential target for therapeutic intervention. Researchers have started exploring technologies such as RNA interference (RNAi) or antisense oligonucleotides to specifically inhibit or degrade RPH3AL-AS1. Preclinical studies utilizing animal models have shown promising results, indicating the feasibility of developing RPH3AL-AS1-targeted therapies in the future. However, further research is needed to optimize delivery systems, assess off-target effects, and evaluate the long-term safety and efficacy of these interventions.

The Importance of Biomarker:

Biomarkers are critical tools in disease diagnosis, prognosis, and monitoring treatment response. RPH3AL-AS1, with its tissue-specific expression and dysregulation in disease conditions, holds potential as a biomarker. Detecting and quantifying RPH3AL-AS1 levels may facilitate early diagnosis, aid in identifying high-risk individuals, and monitor disease progression. Furthermore, RPH3AL-AS1 could serve as a prognostic indicator, allowing clinicians to tailor treatment strategies to individual patients.

Conclusion:

RPH3AL-AS1, a long non-coding RNA transcribed from the RPH3AL gene, has emerged as an intriguing molecule with implications in various diseases. Its dysregulation in cancer, neurological disorders, and cardiovascular diseases highlights its potential as a drug target or biomarker. Targeting RPH3AL-AS1 may provide innovative therapeutic approaches to combat these diseases, while its use as a biomarker could revolutionize diagnosis, prognosis, and treatment monitoring. As research in the field progresses, RPH3AL-AS1 is expected to attract more attention, fueling advancements in personalized medicine.

Protein Name: RPH3AL Antisense RNA 1

The "RPH3AL-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPH3AL-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets